This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Schiff R and Osborne CK (2005) Endocrinology and hormone therapy in breast cancer: new insight into estrogen receptor-α function and its implication for endocrine therapy resistance in breast cancer. Breast Cancer Res 7: 205–211
Winer EP et al. (2005) American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 23: 619–629
Eiermann W et al. (2001) Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol 12: 1527–1532
Roukos DH et al. Surgery in the era of gene expression profiling-based prediction and individualized, neoadjuvant breast cancer therapy: the beginning of the end? Ann Surg Oncol, in press
Brenton JD et al. (2005) Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol 23: 7350–7360
Acknowledgements
The synopsis was written by Petra Roberts, Associate Editor, Nature Clinical Practice.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Roukos, D., Fatouros, M., Paraskevaidis, E. et al. Is an aromatase inhibitor more effective than tamoxifen in neoadjuvant endocrine therapy for breast cancer?. Nat Rev Clin Oncol 3, 82–83 (2006). https://doi.org/10.1038/ncponc0407
Received:
Accepted:
Issue date:
DOI: https://doi.org/10.1038/ncponc0407
